KIYATEC INC

KIYATEC INC specializes in advanced biomedical analytics and predictive modeling for translational research, leveraging proprietary in vitro diagnostic platforms to simulate human tumor responses in real time. Their core technical expertise lies in 3D tissue modeling, computational oncology, and patient-derived tissue analysis, enabling personalized therapy prediction without direct clinical exposure. The company’s differentiated approach combines high-fidelity ex vivo systems with machine learning algorithms to quantify tumor behavior, supporting drug development and clinical trial stratification. This focus on precision oncology tools positions them at the intersection of biotechnology and computational biology, serving as a bridge between preclinical research and clinical decision-making. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal collaboration can be inferred. Similarly, without contract data, no direct link to particular government programs or procurement cycles can be established. KIYATEC INC operates under NAICS 541715, which classifies them as a research and development firm in the life sciences sector, specifically focused on biotechnological research services. Their market positioning centers on providing innovative, data-driven solutions to accelerate oncology drug discovery and reduce reliance on animal models. They serve a niche within the biomedical R&D ecosystem, emphasizing translational science and regulatory-compliant analytical workflows for pharmaceutical and government-funded research entities. The company is structured as a small business (2L) and is headquartered in Greenville, South Carolina. While no government certifications are listed, their technical capabilities align with federal priorities in precision medicine and cancer research. Their geographic presence supports regional biotech ecosystems and collaboration with academic medical centers engaged in federally funded research initiatives.